医生: Roseleen Charania, MD
- 姓 名：Roseleen Charania, MD
- 科 室：内科
- 职 称：
- 就职医院：
- 擅长领域：
- 专家风采
- 专家报道
- 科室团队
- 会诊价格
- 申请专家会诊
Board Certification
Medical Oncology
Hematology
Internal Medicine
Medical School
Goa Medical College, India
Residency
Drexel University College of Medicine, Philadelphia, PA
Fellowship
Hematology & oncology - University of Oklahoma Health Sciences Center, OKlahoma City, OK
Dr. Charania earned her medical degree from Goa Medical College, India. After completing her residency training in Internal Medicine at Drexel University College of Medicine, she attained Board Certification in Internal Medicine in 2007. She has completed her fellowship in Hematology and Medical oncology from the University of Oklahoma Health Sciences Center and obtained her dual Board Certification in 2010. She served as a principle investigator in various studies in Hematology and oncology during her fellowship. She has been in private practice since 2010.
Medical Oncology
Hematology
Internal Medicine
Medical School
Goa Medical College, India
Residency
Drexel University College of Medicine, Philadelphia, PA
Fellowship
Hematology & oncology - University of Oklahoma Health Sciences Center, OKlahoma City, OK
Dr. Charania earned her medical degree from Goa Medical College, India. After completing her residency training in Internal Medicine at Drexel University College of Medicine, she attained Board Certification in Internal Medicine in 2007. She has completed her fellowship in Hematology and Medical oncology from the University of Oklahoma Health Sciences Center and obtained her dual Board Certification in 2010. She served as a principle investigator in various studies in Hematology and oncology during her fellowship. She has been in private practice since 2010.
患者感谢与分享
我要评价
扫描二维码，加入病友群
相关资讯新闻more>>
- 国内八大免疫检查点抑制剂PD-1/PD-L1已上市,pd1/pd-l1免疫治疗,pd1/pd-l1抑制剂,国内pd1/pd-l1价格
- 拉罗替尼价格确定,不同晚期癌症患者的新希望,这些国家已上市
- 晚期肾癌靶向药新药MK-6482(原名PT2977)强势来袭疾病控制率高达80%
- 肿瘤浸润淋巴细胞TILS,TIL疗法,TIL细胞治疗的最新研究进展盘点
- 2020年最新癌症靶向，免疫治疗药物临床试验招募信息汇总！
- 质子治疗肿瘤,质子放疗,质子疗法一个部位照射,全身肿瘤消失
- 什么是细胞免疫疗法,细胞免疫疗法治疗,肿瘤细胞免疫疗法,肿瘤细胞免疫治疗
- 树突状细胞疫苗,树突细胞免疫疗法,DC细胞免疫疗法在各类癌症中的研究进展盘点
- 癌症为什么做基因检测,肿瘤为什么要基因检测
- 吃了两盒泰瑞沙了，再吃易瑞沙，会起相反的作用吗？
医诊通服务
临床试验
全球抗癌快讯 more>>
- 2019年中国排名第一的肿瘤医院,中国肿瘤医院排名,全国肿瘤医院排名TOP100
- 2019全国医院排名,全国医院综合排名,全国医院排名前十名
- 2019年中国全国肿瘤医院排名,全国肿瘤医院前十名,全国医院肿瘤科排名
- 2019中国医院排名排行榜,中国十大医院排名,中国医院排名前十
- 目前最全的PD-1抗体免疫治疗指南民间版
- 告诉癌症患者，癌症全基因检测需要多少钱？
- 靶向药物吃了5年，靶向药肿瘤消失案例
- 知否？奥希替尼耐药机制逐一告破！四大策略助力肺癌精准治疗！
- Ngs检测，Ngs基因检测，Ngs基因检测什么意思
- 第四代肺癌靶向新药EAI045欧美即将上市
- 靶向药物大全，靶向药价格表，哪些靶向药在医保范围
- 乳腺癌靶向药物：帕博西尼Ibrance（palbociclib）显奇效
- 肿瘤突变负荷（TMB）会是下一个生物标记吗？
- Cart治疗、Cart疗法，2019年这两种Cart细胞免疫疗法治疗癌症最值得期待！
- 40张图片带你看清各类肿瘤的真面目！
- 吃靶向药的副作用，靶向药吃多久可以停药，靶向药停后果
- 小细胞肺癌免疫治疗药物Atezolizumab(阿替利珠单抗)Tecentriq(泰圣奇、特善奇、T药),阿特珠单抗价格
- Braf基因检测到V600e突变，Braf基因突变怎么办
- 解读非小细胞肺癌PD-L1新药Durvalumab（中文名德鲁单抗、I药、Imfinzi）
- 靶向药肺癌，最新肺癌第四代靶向药
- 北京301质子治疗中心,涿州一州质子肿瘤医院,涿州质子医院,河北一洲质子肿瘤医院
- 剿灭“恶霸”三阴乳腺癌出绝招，最全治疗进展大盘点（2019.7）
扫描关注我们微信公众号，热线电话：400-666-7998
版权所有·北京环宇达康医疗科技有限责任公司 京ICP备13042754号 京公网安备11010802013088
客服投诉邮箱:doctor.huang@globecancer.com
© 2009-2019 北京环宇达康医疗科技有限责任公司版权所有
提示：本网站只为患者提供疾病资讯服务和医生咨询服务，任何关于疾病的咨询建议均为参考意见，
由患者、医院和主治医师决定和实施治疗方案，本网站和咨询医师不承担由咨询行为引起的法律责任。